Liraglutide (Saxenda)

CADTH recommends that Saxenda should not be reimbursed by public drug plans for chronic weight management in adult patients. Evidence from 3 studies demonstrated that Saxenda was associated with statistically significant reductions in body weight compared with placebo after 56 weeks of treatment. No conclusions could be drawn about long-term benefits, particularly for clinically meaningful improvements in comorbidities identified as priorities by patients, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications. Patients identified a need for treatments that can improve potential obesity-related comorbidities, such as diabetes, sleep apnea, osteoarthritis, and cardiovascular complications. It is not clear whether Saxenda meets these needs.